A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
A phase 1/2 trial of BA3071, Nivolumab, Pembrolizumab in melanoma, run by BioAtla, Inc., active and no longer recruiting.
Overview
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT05180799 by BioAtla, Inc., with 320 participants planned, started 2022-08-03 and due to reach its primary completion in 2025-03-19. Interventions recorded: BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta). Conditions listed: NSCLC, Melanoma. No results are recorded here; the registry entry is the source.
Setting
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
Phase
Phase 1/2
Sponsor
BioAtla, Inc.
Registry
Enrolled
320
Similar pages
not linked directly; found by shared links- TrialA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N
Shares Pemetrexed, Nivolumab, Pembrolizumab.
- IdeaAutomatic price cuts when a cancer drug's approved indications and volumes expand
Shares Nivolumab, Pembrolizumab.
- TrialSafety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC
Shares Pemetrexed, Pembrolizumab.
- TrialEffectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
- TrialA Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
- TrialStudy of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen
Shares Pemetrexed, Melanoma, Pembrolizumab.
- TrialStudy of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Shares Nivolumab, Pembrolizumab.
- TrialMC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma